<DOC>
	<DOC>NCT01715961</DOC>
	<brief_summary>This clinical trial is a multicentric prospective study to assess the clinical and prognostic value of sarcopenia in patients older than 70 years with diffuse large B-cell lymphoma.</brief_summary>
	<brief_title>Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>Sarcopenia status is assessed by CT scan imaging on the overall survival at 18 months in patients older than 70 years with diffuse large B-cell lymphoma treated by R-CHOP.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Sarcopenia</mesh_term>
	<criteria>Patients &gt;= 70 years DLBCL, grade IIIB follicular lymphoma or histologically proven transformed low grade lymphoma Whatever the IPI score and the performance status Treated by RituximabCHOP or RituximabminiCHOP CT scan imaging performed one month or less before inclusion Signed informed consent No initial CT scan imaging performed more than one month before inclusion Positivity for HCV, HBV and HIV Anthracycline contraindication</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>70 years old</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Rituximab-CHOP</keyword>
	<keyword>Sarcopenia</keyword>
</DOC>